Table 1.
Baseline demography and disease characteristics
| Tofacitinib ointment 1 (n = 23) | Vehicle 1 (n = 13) | Tofacitinib Ointment 2 (n = 25) | Vehicle 2 (n = 10) | |
|---|---|---|---|---|
| Sex (male), n (%) | 17 (73·9) | 5 (38·5) | 15 (60·0) | 6 (60·0) |
| Age (years), mean (SD) | 49·3 (14·5) | 50·2 (14·8) | 53·8 (14·4) | 45·9 (12·6) |
| Range | 24–76 | 32–72 | 27–80 | 26–64 |
| Race, n (%) | ||||
| White | 23 (100·0) | 11 (84·6) | 24 (96·0) | 9 (90·0) |
| Other | 0 | 2 (15·4) | 1 (4·0) | 1 (10·0) |
| Weight (kg), mean (SD) | 94·5 (26·0) | 85·8 (12·0) | 89·2 (17·4) | 103·4 (30·3) |
| Range | 58·1–175·0 | 65·8–104·1 | 62·2–122·0 | 61·7–145·2 |
| Body mass index (kg m−2), mean (SD) | 30·6 (8·6) | 30·9 (5·2) | 30·6 (6·9) | 33·1 (8·8) |
| Range | 22·0–63·1 | 24·6–40·7 | 18·6–43·6 | 22·5–44·8 |
| Duration of psoriasis since first diagnosisa (years), mean (range) | 17·1 (0·7–58·4) | 19·1 (0·6–51·8) | 17·7 (2·5–48·2) | 10·5 (2·3–21·5) |
| PASI, mean (SD) | 6·7 (2·51) | 6·7 (1·88) | 5·9 (2·72) | 5·1 (2·93) |
| Range | 3·7–13·5 | 3·6–10·1 | 1·5–13·8 | 2·4–12·4 |
| PGA, mean (SD) | 2·45 (0·47) | 2·41 (0·43) | 2·38 (0·52) | 2·47 (0·45) |
| Range | 2–3 | 2–3 | 2–3 | 2–3 |
| BSAb (%), mean (SD) | 4·4 (2·13) | 5·4 (2·29) | 4·1 (2·40) | 3·3 (2·78) |
| Range | 0·8–10·0 | 2·5–9·5 | 0·9–10·0 | 0·6–10·0 |
| TPSS,c mean (SD) | 7·22 (1·51) | 7·31 (1·38) | 6·80 (1·19) | 7·20 (1·40) |
| Range | 5·0–10·0 | 5·0–9·0 | 5·0–9·0 | 5·0–9·0 |
| TPAd (cm2), mean (SD) | 34·06 (32·59) | 43·73 (31·55) | 30·72 (32·60) | 44·08 (41·02) |
| Range | 9·3–146·2 | 9·3–118·3 | 7·1–142·3 | 11·4–138·6 |
| ISI,e mean (SD) | 4·09 (2·52) | 5·54 (3·10) | 4·36 (2·53) | 6·20 (2·62) |
| Range | 0–9 | 0–10 | 0–8 | 2–10 |
BSA, body surface area; ISI, Itch Severity Item; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; TPA, target plaque area; TPSS, Target Plaque Severity Score.
a
To day 1 of this study;
b
BSA estimated by the handprint method;
c
TPSS ranged from 0 to 12 (increments of 1); higher scores represent greater severity of psoriasis;
d
TPA was measured by tracing the target plaque perimeter and quantifying its size by computer image analysis (planimetry);
e
ISI ranged from 0 (no itching) to 10 (worst possible itching).